US equities
|
MU
$1,035.84
▲+0.00%
SPCX
$160.57
▲+0.00%
NVDA
$230.48
▲+0.00%
AAPL
$340.42
▲+0.00%
SNDK
$1,609.46
▲+0.00%
INTC
$107.08
▲+0.00%
AMD
$620.68
▲+0.00%
LITE
$1,048.60
▲+0.00%
MU
$1,035.84
▲+0.00%
SPCX
$160.57
▲+0.00%
NVDA
$230.48
▲+0.00%
AAPL
$340.42
▲+0.00%
SNDK
$1,609.46
▲+0.00%
INTC
$107.08
▲+0.00%
AMD
$620.68
▲+0.00%
LITE
$1,048.60
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Cognition Therapeutics, Inc. - Common Stock
(NQ:
CGTX
)
0.8952
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cognition Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
12 Health Care Stocks Moving In Monday's After-Market Session
↗
July 07, 2025
Via
Benzinga
Monday's after hours session: top gainers and losers
↗
July 07, 2025
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Via
Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
↗
July 07, 2025
Via
Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session.
↗
July 07, 2025
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via
Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
July 07, 2025
Via
Benzinga
Which stocks are moving after the closing bell on Friday?
↗
July 04, 2025
The US market regular session of Friday is over, let's have a look at the top gainers and losers in the after hours session today.
Via
Chartmill
Cognition Therapeutics Shares Jump 12% After Hours Following Encouraging Phase 2 Alzheimer's Trial Data
↗
July 04, 2025
Cognition Therapeutics Inc (NASDAQ: CGTX) continued to gain 12.10% in after-hours trading on Thursday, after a 20.82% surge during regular market hours.
Via
Benzinga
Sonnet BioTherapeutics Drops 5% Intraday, Rebounds 14% After Hours Amid Delisting Concerns
↗
July 03, 2025
Sonnet BioTherapeutics Holdings Inc. (NASDAQ: SONN) fell 5.54% on Thursday to close at $3.92, before rebounding 14.29% in after-hours trading to $4.48, amid concerns of a potential NASDAQ delisting.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
July 03, 2025
Via
Benzinga
Top movers in Thursday's after hours session
↗
July 03, 2025
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Via
Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
July 03, 2025
Via
Benzinga
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Surpasses 50% Enrollment Target
July 01, 2025
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer’s Disease and Dementia with Lewy Bodies (DLB)
June 25, 2025
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
↗
June 23, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
June 17, 2025
Via
Benzinga
These stocks are moving in today's pre-market session
↗
June 05, 2025
Discover the top movers in Thursday's pre-market session and stay informed about market dynamics.
Via
Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
June 05, 2025
Via
Benzinga
Philanthropic Donor Funds Cognition Therapeutics’ Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
June 03, 2025
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health
May 09, 2025
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
May 08, 2025
Via
Benzinga
Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy
May 08, 2025
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update
May 07, 2025
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer’s Disease Processes
April 01, 2025
Presentation Shows Pronounced Reduction in Key Plasma Biomarkers Among Prespecified Study Population
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer’s Disease in Podium Presentation at AD/PD 2025
March 25, 2025
Additional Analyses to be Presented at AD/PD Include Correlation of CSF Biomarkers with Cognitive Outcomes, and Pharmacodynamic Biomarkers of Target Engagement
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update
March 20, 2025
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
March 14, 2025
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Earnings Scheduled For March 20, 2025
↗
March 20, 2025
Via
Benzinga
Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results
March 13, 2025
Conference Call and Live Audio Webcast Scheduled for March 20, 2025
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing
March 12, 2025
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Life Sciences Investor Forum Agenda Announced for March 13th
March 12, 2025
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
